SG11201703609UA - Methods and formulations for treating vascular eye diseases - Google Patents
Methods and formulations for treating vascular eye diseasesInfo
- Publication number
- SG11201703609UA SG11201703609UA SG11201703609UA SG11201703609UA SG11201703609UA SG 11201703609U A SG11201703609U A SG 11201703609UA SG 11201703609U A SG11201703609U A SG 11201703609UA SG 11201703609U A SG11201703609U A SG 11201703609UA SG 11201703609U A SG11201703609U A SG 11201703609UA
- Authority
- SG
- Singapore
- Prior art keywords
- formulations
- methods
- eye diseases
- treating vascular
- vascular eye
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462084003P | 2014-11-25 | 2014-11-25 | |
US201562147232P | 2015-04-14 | 2015-04-14 | |
US14/943,490 US20160144025A1 (en) | 2014-11-25 | 2015-11-17 | Methods and formulations for treating vascular eye diseases |
PCT/US2015/061543 WO2016085750A1 (en) | 2014-11-25 | 2015-11-19 | Methods and formulations for treating vascular eye diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201703609UA true SG11201703609UA (en) | 2017-06-29 |
Family
ID=56009149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201703609UA SG11201703609UA (en) | 2014-11-25 | 2015-11-19 | Methods and formulations for treating vascular eye diseases |
Country Status (18)
Country | Link |
---|---|
US (3) | US20160144025A1 (ja) |
EP (1) | EP3224278A4 (ja) |
JP (2) | JP2017536414A (ja) |
KR (1) | KR20170087950A (ja) |
CN (1) | CN107001457A (ja) |
AU (1) | AU2015353838A1 (ja) |
BR (1) | BR112017009807A2 (ja) |
CA (1) | CA2968522A1 (ja) |
CL (1) | CL2017001188A1 (ja) |
CO (1) | CO2017004715A2 (ja) |
EA (1) | EA201791168A1 (ja) |
IL (1) | IL252159B (ja) |
MA (2) | MA41028A (ja) |
MX (1) | MX2017006129A (ja) |
PE (1) | PE20170900A1 (ja) |
PH (1) | PH12017500834A1 (ja) |
SG (1) | SG11201703609UA (ja) |
WO (1) | WO2016085750A1 (ja) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2586459T (lt) | 2005-03-25 | 2017-09-25 | Regeneron Pharmaceuticals, Inc. | Vegf antagonisto kompozicijos |
MX2008012991A (es) | 2006-04-07 | 2008-10-17 | Procter & Gamble | Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos. |
ES2406764T3 (es) | 2006-06-16 | 2013-06-10 | Regeneron Pharmaceuticals, Inc. | Formulaciones que comprenden antagonistas de VEGF para administración intravítrea |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
KR101426125B1 (ko) | 2009-07-06 | 2014-08-06 | 에르피오 세러퓨틱스 인코포레이티드 | 암 세포의 전이 예방을 위한 화합물, 조성물 및 방법 |
JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
US11104730B2 (en) | 2013-11-20 | 2021-08-31 | Regeneren Pharmaceuticals, Inc. | Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors |
WO2015138882A1 (en) | 2014-03-14 | 2015-09-17 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
TWI761959B (zh) | 2014-11-07 | 2022-04-21 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
US10952992B2 (en) | 2015-09-23 | 2021-03-23 | Aerpio Pharmaceuticals, Inc. | Methods of treating intraocular pressure with activators of Tie-2 |
CA3010056A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
AU2017299581B2 (en) | 2016-07-20 | 2024-05-23 | EyePoint Pharmaceuticals, Inc. | Humanized monoclonal antibodies that target ve-ptp (hptp-β) |
WO2018070390A1 (ja) * | 2016-10-12 | 2018-04-19 | 第一三共株式会社 | 抗robo4抗体と他剤を含む組成物 |
MX2019012985A (es) * | 2017-05-06 | 2020-01-13 | Regeneron Pharma | Métodos para tratar trastornos oculares con antagonistas de aplnr e inhibidores de vegf. |
KR102584848B1 (ko) * | 2017-08-18 | 2023-10-04 | 리제너론 파마슈티칼스 인코포레이티드 | 샘플 매트릭스에서 단백질 변이체를 분석하기 위한 이미지 모세관 등전 집속 |
WO2019124946A1 (ko) * | 2017-12-22 | 2019-06-27 | 삼성바이오에피스 주식회사 | Vegf 길항제를 포함하는 액상 조성물 |
EP3743091A4 (en) | 2018-01-26 | 2021-12-15 | The Regents of the University of California | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANGIOGENIC DISORDERS USING ANTI-VEGF AGENTS |
CN111699004A (zh) * | 2018-02-06 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 眼科疾病的治疗 |
US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
WO2019173767A1 (en) * | 2018-03-08 | 2019-09-12 | Coherus Biosciences Inc. | Stable aqueous formulations of aflibercept |
CN108671229B (zh) * | 2018-05-08 | 2022-03-25 | 华博生物医药技术(上海)有限公司 | 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂 |
EP3790532A1 (en) | 2018-05-10 | 2021-03-17 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
WO2020037309A1 (en) * | 2018-08-17 | 2020-02-20 | Trican Biotechnology Co., Ltd. | Anti-angiogenesis fusion protein and uses thereof |
CN109598628B (zh) * | 2018-11-30 | 2022-09-20 | 平安医疗健康管理股份有限公司 | 医保欺诈行为的识别方法、装置、设备及可读存储介质 |
CR20210318A (es) | 2018-12-18 | 2021-07-14 | Novartis Ag | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf |
EP3927729A4 (en) | 2019-02-18 | 2023-10-11 | Eli Lilly and Company | THERAPEUTIC ANTIBODY FORMULATION |
JP2022530657A (ja) | 2019-04-29 | 2022-06-30 | アイポイント ファーマシューティカルズ, インコーポレイテッド | シュレム管を標的とするTie-2活性化物質 |
CN110423281B (zh) * | 2019-07-31 | 2021-04-30 | 成都金唯科生物科技有限公司 | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
WO2021108255A1 (en) | 2019-11-25 | 2021-06-03 | The Regents Of The University Of California | Long-acting vegf inhibitors for intraocular neovascularization |
CN113493519B (zh) * | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
CA3190173A1 (en) * | 2020-06-22 | 2021-12-30 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-ang-2 antibody and use thereof |
KR20220013343A (ko) * | 2020-07-24 | 2022-02-04 | (주) 팬젠 | 안과용 액상 조성물 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
WO2005072772A1 (en) * | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
ES2406764T3 (es) | 2006-06-16 | 2013-06-10 | Regeneron Pharmaceuticals, Inc. | Formulaciones que comprenden antagonistas de VEGF para administración intravítrea |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
CA2665956A1 (en) * | 2009-05-07 | 2010-11-07 | Samir Patel | Combination treatment for ocular diseases |
JP2012528112A (ja) | 2009-05-28 | 2012-11-12 | グラクソ グループ リミテッド | 抗原結合タンパク質 |
US8980268B2 (en) * | 2009-07-29 | 2015-03-17 | Regeneron Pharamceuticals, Inc. | Methods for treating cancer by administering an anti-Ang-2 antibody |
JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
US20120189635A1 (en) * | 2009-07-29 | 2012-07-26 | Regeneron Pharmaceuticals, Inc. | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) |
AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
KR20180023015A (ko) | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
EA033387B1 (ru) * | 2012-01-23 | 2019-10-31 | Regeneron Pharma | СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2 |
AU2013288641B2 (en) * | 2012-07-13 | 2017-07-06 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
MX368067B (es) * | 2012-12-05 | 2019-09-18 | Novartis Ag | Composiciones y métodos para dirigir anticuerpos a la eritropoyetina (epo). |
JO3405B1 (ar) * | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
US20160159893A1 (en) * | 2013-07-11 | 2016-06-09 | Gabriela Burian | Use of a VEGF Antagonist in Treating Retinopathy of Prematurity |
US9914769B2 (en) * | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
DE112014005975T5 (de) * | 2013-12-17 | 2016-09-15 | Kymab Limited | Menschliche Ziele |
-
2015
- 2015-11-17 US US14/943,490 patent/US20160144025A1/en not_active Abandoned
- 2015-11-18 MA MA041028A patent/MA41028A/fr unknown
- 2015-11-19 AU AU2015353838A patent/AU2015353838A1/en not_active Abandoned
- 2015-11-19 CN CN201580063632.5A patent/CN107001457A/zh active Pending
- 2015-11-19 SG SG11201703609UA patent/SG11201703609UA/en unknown
- 2015-11-19 EA EA201791168A patent/EA201791168A1/ru unknown
- 2015-11-19 MX MX2017006129A patent/MX2017006129A/es unknown
- 2015-11-19 WO PCT/US2015/061543 patent/WO2016085750A1/en active Application Filing
- 2015-11-19 MA MA40306A patent/MA40306A1/fr unknown
- 2015-11-19 JP JP2017545861A patent/JP2017536414A/ja active Pending
- 2015-11-19 CA CA2968522A patent/CA2968522A1/en not_active Abandoned
- 2015-11-19 KR KR1020177017473A patent/KR20170087950A/ko unknown
- 2015-11-19 BR BR112017009807A patent/BR112017009807A2/pt not_active IP Right Cessation
- 2015-11-19 PE PE2017000901A patent/PE20170900A1/es unknown
- 2015-11-19 EP EP15862329.8A patent/EP3224278A4/en not_active Withdrawn
-
2016
- 2016-12-06 US US15/370,896 patent/US20170080086A1/en not_active Abandoned
-
2017
- 2017-05-05 PH PH12017500834A patent/PH12017500834A1/en unknown
- 2017-05-08 IL IL252159A patent/IL252159B/en active IP Right Grant
- 2017-05-10 CO CONC2017/0004715A patent/CO2017004715A2/es unknown
- 2017-05-10 CL CL2017001188A patent/CL2017001188A1/es unknown
-
2018
- 2018-12-28 US US16/235,221 patent/US11071780B2/en active Active
-
2020
- 2020-12-04 JP JP2020201473A patent/JP2021046431A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20170087950A (ko) | 2017-07-31 |
CN107001457A (zh) | 2017-08-01 |
MA40306A1 (fr) | 2019-03-29 |
JP2021046431A (ja) | 2021-03-25 |
IL252159A0 (en) | 2017-07-31 |
US20190117767A1 (en) | 2019-04-25 |
BR112017009807A2 (pt) | 2018-02-27 |
MX2017006129A (es) | 2018-04-10 |
CL2017001188A1 (es) | 2017-11-24 |
EA201791168A1 (ru) | 2017-09-29 |
JP2017536414A (ja) | 2017-12-07 |
PE20170900A1 (es) | 2017-07-12 |
AU2015353838A1 (en) | 2017-06-08 |
US11071780B2 (en) | 2021-07-27 |
CO2017004715A2 (es) | 2017-09-20 |
MA41028A (fr) | 2017-10-03 |
US20160144025A1 (en) | 2016-05-26 |
IL252159B (en) | 2021-03-25 |
EP3224278A1 (en) | 2017-10-04 |
US20170080086A1 (en) | 2017-03-23 |
EP3224278A4 (en) | 2018-07-11 |
PH12017500834A1 (en) | 2017-10-30 |
CA2968522A1 (en) | 2016-06-02 |
WO2016085750A1 (en) | 2016-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL252159B (en) | Methods and formulations for the treatment of diseases of the blood vessels of the eye | |
IL283561B (en) | Methods for treating eye diseases | |
HK1258588A1 (zh) | 用於治療眼科疾病的化合物和製劑 | |
IL246791A0 (en) | Compositions and methods for treating eye diseases | |
HK1231417A1 (zh) | 用於治療眼科疾病和障礙的化合物 | |
HK1246179A1 (zh) | 治療視網膜疾病的方法 | |
SG11201706755SA (en) | Methods and compositions for treating genetic eye diseases | |
HK1245641A1 (zh) | 次氯酸製劑及治療皮膚病的方法 | |
EP3030275A4 (en) | Method of treating peripheral artery diseases in lower limbs | |
EP3139928A4 (en) | Anordrin compositions and methods for treating diseases | |
HK1245127A1 (zh) | 治療腦疾病的方法和組合物 | |
EP3110446A4 (en) | Methods and compositions for treating siglec-8 associated diseases | |
EP3030274A4 (en) | Method of treating peripheral artery diseases in lower limbs | |
EP3030276A4 (en) | Method of treating peripheral artery diseases in lower limbs | |
IL252904A0 (en) | Methods and factors for treating diseases | |
EP3265103A4 (en) | Compositions and methods for treating ocular diseases | |
HK1244782A1 (zh) | 用於治療疾病和病癥的組合物和方法 | |
HK1243937A1 (zh) | 治療疾病的方法 | |
SG11202005278PA (en) | Compounds for treating eye diseases and methods thereof | |
EP3386503A4 (en) | METHOD AND FORMULATIONS FOR THE TREATMENT OF VASCULAR DISEASES | |
IL246608A0 (en) | Preparations and methods for treating heart disease | |
EP3188744A4 (en) | Methods for treatment and prevention of vascular disease | |
AU2014903547A0 (en) | Method for treatment and prevention of vascular disease |